**Title:** Intrapulmonary pharmacokinetics of first-line anti-TB drugs in Malawian tuberculosis patients

**Authors:** Andrew D McCallum 1,2,3, Henry E Pertinez 3, Laura J Else 3, Sujan Dilly-Penchala 3, Aaron P Chirambo 1, Irene Sheha 1, Madalitso Chasweka 1, Alex Chitani 1, Rose D Malamba 1, Jamilah Z Meghji 1,2, Stephen B Gordon 1,2, Geraint R Davies 3, Saye H Khoo 3, Derek J Sloan 4,\*, Henry C Mwandumba 1,2,\*

\* Contributed equally as senior authors

**Affiliations:**

1. Malawi-Liverpool-Wellcome Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi
2. Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK
3. Institute of Translational Medicine, University of Liverpool, Liverpool, UK
4. School of Medicine, University of St Andrews, St Andrews, UK

**Keywords:** tuberculosis, pulmonary; pharmacokinetics; pharmacodynamics; antibiotics, antitubercular

**Running title:** Intrapulmonary PK of anti-TB drugs

**Corresponding author’s details:** Dr Andrew D McCallum, C/O Department of Infection,Imperial College Healthcare NHS Trust, The Bays, South Wharf Road, St Mary’s Hospital, London W2 1NY, UK, Tel: +44 (0)20 3311 3311, E-mail: andrew.mccallum@nhs.net

**Alternate corresponding author’s details:** Prof Henry Mwandumba, C/O Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK, Tel: +265 881 073 822, E-mail: Henry.Mwandumba@lstmed.ac.uk

**Summary:**

First-line anti-tuberculosis drugs achieve higher concentrations in the lung than in plasma in patients on treatment. Despite standard weight-based dosing, rifampicin concentrations are particularly low in plasma, epithelial lining fluid and alveolar cells. Dose refinement may be required.

**Abstract**

**BACKGROUND:** Further work is required to understand the intrapulmonary pharmacokinetics of first-line anti-tuberculosis drugs. This study aimed to describe the plasma and intrapulmonary pharmacokinetics of rifampicin, isoniazid, pyrazinamide, and ethambutol, and explore relationships with clinical treatment outcomes in patients with pulmonary tuberculosis.

**METHODS:** Malawian adults with a first presentation of microbiologically-confirmed pulmonary tuberculosis received standard 6-month first-line therapy. Plasma and intrapulmonary samples were collected 8 and 16 weeks into treatment and drug concentrations measured in plasma, lung/airway epithelial lining fluid, and alveolar cells. Population pharmacokinetic modelling generated estimates of drug exposure (Cmax and AUC) from individual-level post-hoc Bayesian estimates of plasma and intrapulmonary pharmacokinetics.

**RESULTS:** One-hundred-and-fifty-seven patients (58% HIV co-infected) participated. Despite standard weight-based dosing, peak plasma concentrations of first-line drugs were below therapeutic drug monitoring targets. Rifampicin concentrations were low in all three compartments. Isoniazid, pyrazinamide, and ethambutol achieved higher concentrations in epithelial lining fluid and alveolar cells than plasma. Isoniazid and pyrazinamide concentrations were 14.6 (95% CI: 11.2-18.0) and 49.8-fold (95% CI: 34.2-65.3) higher in lining fluid than plasma respectively. Ethambutol concentrations were highest in alveolar cells (alveolar cells:plasma ratio 15.0, 95% CI 11.4-18.6). Plasma or intrapulmonary pharmacokinetics did not predict clinical treatment response.

**CONCLUSIONS:** We report differential drug concentrations between plasma and the lung. While plasma concentrations were below therapeutic monitoring targets, accumulation of drugs at the site of disease may explain the success of the first-line regimen. The low rifampicin concentrations observed in all compartments lend strong support for ongoing clinical trials of high-dose rifampicin regimens.

**Introduction**

Whilst effective antibiotics for tuberculosis (TB) have been widely available for several decades, cure rates in high burden countries remain variable [1]. Revisiting the pharmacokinetics-pharmacodynamics of first-line agents, in patients with active pulmonary disease, may identify opportunities to optimise or abbreviate anti-TB treatment.

Plasma pharmacokinetic indices for first-line anti-TB drugs vary by up to 10-fold between individuals [2–5] and their relationship with treatment response has varied across studies using differing methodologies [6–10]. We hypothesised that intrapulmonary pharmacokinetics will vary between individuals and may explain drug exposure-response relationships. Novel work using lung explants and spatial mass spectrometry has demonstrated gradients of both drug exposure and *Mycobacterium tuberculosis* drug-sensitivity in granulomas and cavities [11,12], but can only be performed in a small subset of patients with advanced disease.

In this study, drug concentrations in lung epithelial lining fluid and alveolar cells were used to assess intrapulmonary penetration, as expressed by epithelial lining fluid:plasma or alveolar cells:plasma concentration ratios. These ratios, described for a wide range of antimicrobials [13,14], may inform an assessment of whether penetration is sufficient when related to the minimum inhibitory concentration for the infecting organism [15,16]. Few existing healthy volunteer-based data suggest extensive variability in the pulmonary penetration of first-line anti-TB drugs, with potentially sub-therapeutic concentrations of rifampicin and isoniazid in epithelial lining fluid in a proportion of subjects [17–22]. These studies have limitations, however, as no patients with TB participated, drugs were given individually rather than in clinically relevant combinations, and sampling was limited to single fixed time-points.

To address these limitations, we used bronchoalveolar lavage coupled with population pharmacokinetic modelling to assess site of disease pharmacokinetics in a cohort of adult pulmonary TB patients receiving first-line anti-TB treatment.

**Methods**

*Study design*

This was a prospective, single-centre, pharmacokinetic-pharmacodynamic study. Participants were sequentially assigned to two study arms – a plasma arm and an intrapulmonary arm - at a 2:1 allocation ratio.

The primary objective was to describe the pharmacokinetics (area-under-the-concentration-time-curve [AUC] and peak concentration [Cmax]) of rifampicin, isoniazid, pyrazinamide, and ethambutol in plasma, lung epithelial lining fluid, and alveolar cells. The secondary objective was to relate the pharmacokinetic indices to clinical treatment response.

*Study participants*

The study was conducted at Queen Elizabeth Central Hospital in Blantyre, Malawi, between January 2016 and October 2018. Patients registering for first-line treatment for TB at the hospital, or at health centres in urban Blantyre, were screened. Adults aged 16-65 years with sputum smear- or Xpert MTB/RIF-positive pulmonary TB were eligible while those with absolute or relative contraindications to research bronchoscopy were excluded [23] (**Supplementary Materials**). Baseline chest radiographs were scored for severity of disease [24].

Participants received daily fixed-dose combination tablets according to a WHO-approved weight-adjusted regimen and national guidelines [25]. All participants had HIV antibody tests and those who tested positive received antiretroviral therapy [26]. Participants were followed up for 18 months. Adherence was monitored by direct questioning and pill counts.

*Pharmacokinetic sampling*

Pharmacokinetic sampling was completed at 7-8 and 15-16 weeks into TB treatment. All participants were observed to take their anti-TB treatment after an overnight fast. Those in the plasma arm had blood samples collected at 1 and 3 or 2 and 4 hours post-dose. Those in the intrapulmonary arm had blood samples collected pre-dose, and at 0.5, 1, 3, 5 or 2, 4, 6, 8 hours post-dose.

Participants in the intrapulmonary arm had a research bronchoscopy at 2, 4, or 6 hours post-dose. Bronchoscopy was performed as previously described [23], with lavage of the right middle lobe. A cell count was obtained by haemocytometry, before centrifugation to obtain samples of cell pellet and supernatant. The volume of epithelial lining fluid in bronchoalveolar lavage was calculated using the urea dilution method [13,17–20].

Rifampicin, isoniazid, pyrazinamide and ethambutol concentrations were measured in plasma, bronchoalveolar lavage supernatant, and cell pellets with a four-drug liquid chromatography / tandem mass spectrometry assay using appropriate internal standards validated to internationally recognized acceptance criteria (**Supplementary Materials**).

*Pharmacokinetic modelling*

Population pharmacokinetic models were developed using NONMEM© (version 7.4.0, ICON Development Solutions). A two-stage model-building strategy was used: first the plasma-only pharmacokinetic models were developed for each drug, then the plasma and intrapulmonary pharmacokinetic data were analysed under a combined model (**Supplementary Materials**).

One- and two-compartment pharmacokinetic disposition models with alternative models of absorption were explored in fittings to the plasma data. Base model selection was achieved using likelihood ratio testing with the minimum objective function value as the criterion, and examination of relative standard error values and goodness-of-fit plots. Stepwise generalised additive modelling was then used to identify significant covariates for the model (from among age, weight, body mass index, sex, HIV status, and creatinine clearance). The plasma models were evaluated using visual predictive checks.

Concentrations in the epithelial lining fluid and alveolar cell compartments were characterised by ratio parameters relative to their plasma concentration (*RELF* and *RAC* respectively). Interindividual variability on *RELF* and *RAC* was incorporated using an exponential error model with separate residual error variances estimated for both epithelial lining fluid and alveolar cells. *RELF* is based on total drug (protein-unbound plus bound), whereas only the unbound fraction is pharmacologically-active and able to be transported or diffuse into the epithelial lining fluid [27]. Of the four first-line drugs, only rifampicin has extensive protein binding. Assuming an unbound fraction of rifampicin in plasma of 20% [27], and negligible protein binding in epithelial lining fluid [28], we approximated the *RELF/unbound-plasma* ratio to be five-fold greater than *RELF/total-plasma*.

Model-based estimates of individual values of AUC*,* Tmax, and Cmax were calculated from empirical Bayes estimates of parameters (**Supplementary Materials**). Plasma Cmax estimates were compared to therapeutic drug monitoring targets: rifampicin ≥ 8 μg/ml, isoniazid ≥ 3 μg/ml, pyrazinamide ≥ 20 μg/ml, and ethambutol ≥ 2 μg/ml [29]. Rifampicin AUC > 13 μg.h/ml, isoniazid AUC > 52 μg.h/ml, pyrazinamide Cmax > 35 μg/ml and AUC > 363 μg.h/ml were also considered given associations with improved outcomes in one analysis [7,30].

*Treatment response and bacteriology*

Sputum samples were collected at treatment initiation, 2-months, and at end-of-treatment. Baseline drug susceptibility of screening isolates was measured on custom-made microtitre plates (UKMYC3 Sensititre, Thermo Scientific). These assays used 96-well plates with increasing concentrations of rifampicin (0.015-16 µg/ml), isoniazid (0.015-16 µg/ml), and ethambutol (0.25-16 µg/ml) (**Supplementary Materials**).

Two-month culture conversion in liquid media was captured. Participants with negative TB sputum cultures from end-of-treatment onwards or who stopped coughing and remained well after treatment were defined as having a favourable clinical outcome. Recurrent TB (relapse/re-infection), failed treatment, and death were grouped together as unfavourable clinical outcomes. Logistic regression, chi-squared test, and Fisher’s exact test were used to assess relationships between pharmacokinetics and treatment response.

*Ethics*

Ethical approval was obtained from the Research Ethics Committees of the College of Medicine, University of Malawi, and the Liverpool School of Tropical Medicine.

**Results**

*Demographic and clinical description of cohort*

We recruited 157 adult patients with pulmonary TB (**Table 1**). Median age was 34 years (IQR: 28-39), 76.4% were male (120/157), and 58.0% had HIV co-infection (91/157). More than half of co-infected participants (57.1%, 52/91) were diagnosed with HIV during TB diagnosis.

Use of fixed-dose combination regimens resulted in administration of a median rifampicin dose of 9.4 mg/kg (IQR 8.8-10.3), isoniazid 4.7 mg/kg (IQR 4.4-5.1), pyrazinamide 25.2 mg/kg (IQR 23.5-27.4), and ethambutol 17.3 mg/kg (IQR 16.2-18.8). Four (2.5%) participants were under-dosed for rifampicin and isoniazid, and 5 (3.2%) for ethambutol according to the WHO recommended range (rifampicin 10 mg/kg, isoniazid 5 mg/kg, pyrazinamide 25 mg/kg, ethambutol 15 mg/kg)[31]. No correlation was seen between the radiological extent of right midzone disease and intrapulmonary drug concentration (**Supplementary** **Figure 1**).

*Rifampicin pharmacokinetics*

The rifampicin dataset comprised 741 plasma concentration-time observations from 140 participants. The plasma data were best described by a one-compartment disposition model with first-order absorption and elimination. Only sex and HIV status were identified as significant covariates: the final model showed 32% greater clearance in male participants (CL/F; 16.1 L/h male versus 12.2 L/h female), and 34% greater volume of distribution in HIV-infected participants (V/F; 29.7 L HIV-infected versus 22.2 L HIV-uninfected). The visual predictive check and goodness-of-fit plots indicated that the final plasma model performed adequately (**Supplementary Figures 2 and 3**).

Rifampicin concentrations in epithelial lining fluid and alveolar cells exceeded those in plasma. Eighty-three sparse concentration-time observations in epithelial lining fluid and 89 in alveolar cells, from 51 participants, were included in the final combined intrapulmonary model. The final model parameters are included in **Supplementary Table 1**. The extent of distribution to epithelial lining fluid was near double that of plasma with typical predicted *RELF* of 1.97 (95% CI: 1.65-2.30) and was elevated for alveolar cells also (*RAC* 1.35 [95% CI: 0.89-1.81]). After accounting for plasma protein binding, the *RELF/unbound-plasma* ratio will be approximately five-fold greater than the *RELF/total-plasma* recorded here: 9.85 compared to 1.97.

Rifampicin drug exposure in plasma was low relative to therapeutic drug monitoring targets (C­max 4.0 μg/ml [3.5-4.8] for total drug, target ≥ 8 μg/ml [29]; **Figure 1** and **Table 2**). Rifampicin drug exposure was greatest in the epithelial lining fluid compared to plasma and alveolar cells.

*Isoniazid pharmacokinetics*

The isoniazid plasma dataset contained 750 concentration-time observations from 140 participants, best described by a one-compartment pharmacokinetic model with first-order absorption and elimination. Two-compartment models were met with some improvement in the objective function value, but unacceptably poor precision of parameter estimates. Weight as an effect on volume of distribution (V/F) was the only covariate that significantly improved the model fit, with the volume of distribution increasing by 1.08 L for every kg above the population mean of 51.1 kg.

Eighty-eight epithelial lining fluid and 89 alveolar cell concentration-time observations from 51 participants were available for the second stage of modelling. Isoniazid distributed extensively to epithelial lining fluid, with concentrations nearly 15-fold greater than plasma (*RELF* 14.6 [95% CI: 11.2-18.0], **Supplementary Table 1**). Concentrations in alveolar cells were closer to plasma (*RAC* 1.31 [95% CI: 0.95-1.67]). The high concentrations achieved in epithelial lining fluid are demonstrated on the summary concentration-time plot (**Figure 1**) and estimates in **Table 2**.

*Pyrazinamide pharmacokinetics*

Four-hundred-and-nine observations from 131 participants were modelled. Inclusion of weight as a covariate for both clearance (CL/F) and volume of distribution (V/F) significantly improved the model fit.

Fifty concentration-time observations were available for intrapulmonary pharmacokinetic modelling (**Supplementary Table 1**). Pyrazinamide was extensively distributed to epithelial lining fluid, achieving a *RELF* of 49.8 (95% CI: 34.2-65.3). Median pyrazinamide Cmax in epithelial lining fluid was 1,195 μg/ml (IQR 1,062-1,361), as compared to 24.0 μg/ml (IQR 22.2-26.3) in plasma (**Table 2**). Pyrazinamide was observed to accumulate in alveolar cells, with concentrations 3.18-fold greater than plasma (95% CI: 1.90-4.46). No patients achieved the proposed Cmax target of > 35 μg/ml, while only 37 (23.1%) patients achieved an AUC > 363 μg.h/ml.

*Ethambutol pharmacokinetics*

Four-hundred-and-sixteen ethambutol plasma concentration-time observations were modelled. Again, a one-compartment disposition model with first-order absorption was sufficient to describe the data and attempts to use a two-compartment system or incorporate an absorption lag phase were met with non-convergence. After stepwise backwards elimination, only creatinine clearance as an effect on clearance (CL/F) was retained as a covariate in the model.

Fifty epithelial lining fluid and alveolar cell concentration-time observations for ethambutol were available. Final parameter estimates from the final intrapulmonary pharmacokinetic model show that in contrast to the other 3 first-line drugs, highest ethambutol levels were seen in the alveolar cells (*RAC* 15.0 [95% CI: 11.4-18.6], **Supplementary Table 1** and **Figure 1**), while concentrations in epithelial lining fluid were 4-fold higher than plasma (95% CI: 3.3-4.6). While median plasma Cmaxwas low at 1.3 μg/ml (IQR 1.1-1.6), higher peak concentrations of 5.2 μg/ml (IQR 4.2-6.6) and 20.0 μg/ml (15.4-25.3) were seen in epithelial lining fluid and alveolar cells respectively.

*Drug susceptibility*

Baseline isolates (n=88) were highly sensitive to rifampicin: the modal minimum inhibitory concentration (MIC) was 0.015, 0.03, and 0.5 μg/ml for rifampicin, isoniazid, and ethambutol respectively (**Figure 2**). One-hundred-thousand AUC, Cmax, and MIC values were generated from the mean and standard deviation using Monte Carlo simulation, and used to describe the likely distribution of AUC/MIC and Cmax/MIC in this cohort (**Table 3**).

*Relationship with clinical outcome*

One-hundred-and-twenty-six participants had sufficient data to assess 2-month culture conversion: 81 (64%) had stable culture conversion by 2-months. Clinical outcome was captured in 133 participants, with 15 (11%) unfavourable outcomes recorded. Two-month culture conversion was not predictive of clinical outcome (*p*<0.05; McNemar’s hypothesis test for paired data). We observed no relationship between rifampicin AUC > 13 μg.h/ml, isoniazid AUC > 52 μg.h/ml, or pyrazinamide AUC > 363 μg.h/ml and clinical outcome (*p*=1.000, Fisher’s exact test), nor any association between baseline MIC and 2-month culture conversion or final outcome by logistic regression. None of the plasma or intrapulmonary pharmacokinetic parameters were associated with culture conversion or late clinical outcome (**Table 4**).

**Discussion**

We observed low plasma drug concentrations for all four first-line anti-TB drugs in Malawian adults, relative to established therapeutic drug monitoring targets [29]. In addition, we report differences in drug concentrations between plasma and pulmonary compartments. Rifampicin concentrations were low in both compartments, suggesting that the current recommended dose is not optimal. While plasma concentrations of isoniazid, pyrazinamide and ethambutol were also low, these drugs achieved higher concentrations in epithelial lining fluid and alveolar cells; accumulation at the tissue site of disease may be important for the success of first-line anti-TB therapy.

The observed low plasma drug concentrations were consistent with other studies of steady-state pharmacokinetics from TB patients in high-endemicity settings [2,32–35]. Target concentrations for therapeutic drug monitoring were derived from descriptions of drug exposure in both patients and healthy volunteers, and have been associated with clinical outcomes in some studies [10,29]. Furthermore, most patients in our study did not achieve the proposed Cmax (pyrazinamide: 35 μg/ml) or AUC cut-offs (isoniazid: 52 μg.h/ml; pyrazinamide: 363 μg.h/ml) identified as predictive of long-term response [7]. Taken together, we suggest that current dosing might be too low to achieve pharmacokinetic targets.

All four drugs achieved higher concentrations in epithelial lining fluid and alveolar cells than plasma, with isoniazid and pyrazinamide 15- and 50-fold higher in lining fluid than plasma respectively, and ethambutol concentrating within the cells. Our findings differ from previous work, where rifampicin epithelial lining fluid concentrations were reported to be one-fifth of plasma concentrations [17], and less extensive distribution of isoniazid and pyrazinamide to lining fluid was observed [18,19]. Whereas previous work occurred in healthy volunteers (with or without HIV infection), the samples in the present study came from a cohort of adult patients with active pulmonary TB, many of whom were significantly immunosuppressed. Active inflammation, with increased permeability, cellular influx, and disruption of the blood-alveolar barrier may alter tissue drug penetration in those with ongoing infection [27]. Peak intrapulmonary concentrations were seen 2 hours after drug administration, suggesting that single pharmacokinetic measurements at 4 hours in previous studies underestimated drug exposure.

Despite low plasma drug concentrations, 89% of our cohort had a favourable clinical outcome. AUC/MIC and Cmax/MIC for first-line drugs have been described as drivers of treatment efficacy in pre-clinical models [36–39], but local variation in MICs of non-genotypically resistant *Mycobacterium tuberculosis* isolates against first-line TB drugs have not been well described. High plasma and intrapulmonary AUC/MIC and C­max/MIC ratios [8,38] were achieved in this cohort as a result of steady-state accumulation of drugs at the site of disease, coupled with preserved drug sensitivity, particularly for rifampicin.

Dose optimisation may yield further improvements in treatment outcomes. Only two-thirds (64%) of the patients had culture converted by 2-months, despite drug-sensitive disease, good adherence, and intensive follow-up. We postulate that the slow bacillary clearance and unfavourable clinical outcomes are a consequence of the observed plasma and intrapulmonary rifampicin exposure. Rifampicin dosing studies have demonstrated that increased dosing may be associated with supra-proportional increases in plasma AUC [40] and improved early bactericidal activity [41]. These studies have typically used mg/kg doses several fold greater than used in the present study, which may markedly increase rifampicin exposure within the intrapulmonary compartment. HIV-infected participants were observed to have a greater volume of distribution for rifampicin, likely reflecting reduced bioavailability in co-infected patients [42].

We were unable to detect a relationship between plasma or intrapulmonary pharmacokinetics and treatment response in this cohort using standard approaches. Exploratory methods such as those based on machine learning might offer further insights into these relationships and may form the basis of future work. Given a relatively narrow exposure across a constant mg/kg range using weight-banded dosing, studies assessing a greater range of dosing may be required to fully delineate relationships between pharmacokinetics and binary clinical outcomes. Alternatively, modelled bacillary elimination rates, as a continuous measure of treatment response, may identify pharmacokinetic-pharmacodynamic relationships from studies of fewer participants [41,43]. Even if dose refinement is not associated with improved rates of relapse-free cure, identification of factors associated with more rapid bacillary elimination may be important for interruption of transmission and reduction of post-TB lung disease.

There were several limitations to our study. Bronchoalveolar lavage may result in drug efflux from macrophages, but these effects were minimised by placing samples on ice, and rapid centrifugation. The cell pellet obtained from bronchoalveolar lavage contains a mixture of alveolar macrophages, epithelial cells, lymphocytes and other leukocytes, and the drug concentration is recorded in μg/ml of cells. Alveolar macrophages represent more than 80% of cells in lavage, and are the largest cells retrieved [23], and as such, the alveolar cell concentrations are more likely to be an underestimation of macrophage drug concentration. Finally, we were only able to measure MICs from a subset of baseline isolates, instead using summary estimates to describe AUC/MIC and Cmax/MIC distributions for the cohort.

These are the only data describing the steady-state intrapulmonary pharmacokinetics of first-line anti-TB therapy in patients with pulmonary disease. Ultimately, understanding the mismatch in antibiotic exposure between plasma and site of infection may aid dose refinement and development of optimal pan-TB regimens for both drug-sensitive and drug-resistant disease.

**Acknowledgements**

We would like to thank the staff of the Clinical Investigation Unit, Ward 3A, and Radiology Department, Queen Elizabeth Central Hospital, the TB Officers of the Blantyre District Health Office and the Malawi-Liverpool-Wellcome Clinical Research Programme for their support and co-operation during the study. We are grateful to Jehan Ghany and Elizabeth Joekes for their work on the chest radiograph scoring. Lisa Stone, Liverpool School of Tropical Medicine, was integral to some of the laboratory work described in this manuscript but sadly passed away before it was completed; we gratefully acknowledge her contribution. Finally, we would like to thank all study participants for their enthusiastic participation in the study, without whom this work would not be possible.

**Funding**

This work was supported by a Wellcome Trust Clinical PhD Fellowship (105392/B/14/Z to A.D.M.). The Malawi-Liverpool-Wellcome Clinical Research Programme is supported by a strategic award from the Wellcome Trust. We also acknowledge infrastructural support for bioanalysis from the Liverpool Biomedical Research Centre funded by Liverpool Health Partners.

**Potential conflicts of interest**. All authors: no potential conflicts of interest.

**References**

1. World Health Organization. Global Tuberculosis Report 2019. 2019;

2. Wilkins JJ, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin Pharmacol **2011**; 72:51–62. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21320152.

3. Jonsson S, Davidse A, Wilkins J, et al. Population pharmacokinetics of ethambutol in South African tuberculosis patients. Antimicrob Agents Chemother **2011**; 55:4230–4237. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21690284.

4. Wilkins JJ, Savic RM, Karlsson MO, et al. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother **2008**; 52:2138–2148. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18391026.

5. Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J Clin Pharmacol **2006**; 62:727–735. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16685561.

6. Swaminathan S, Pasipanodya JG, Ramachandran G, et al. Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests. Clin Infect Dis **2016**; 63:S63–S74. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27742636.

7. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis **2013**; 208:1464–1473. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23901086.

8. Chigutsa E, Pasipanodya JG, Visser ME, et al. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother **2015**; 59:38–45. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25313213.

9. Rockwood N, Pasipanodya JG, Denti P, et al. Concentration-dependent antagonism and culture conversion in pulmonary tuberculosis. Clin Infect Dis **2017**; 64:1350–1359. Available at: https://watermark.silverchair.com/cix158.pdf?token=AQECAHi208BE49Ooan9kkhW\_Ercy7Dm3ZL\_9Cf3qfKAc485ysgAAAaMwggGfBgkqhkiG9w0BBwagggGQMIIBjAIBADCCAYUGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMRAmRApCojrgcIyMiAgEQgIIBVhxC5naUckSiOO733ceobJW4EwlkWYQ1zkl1FfjtKp9MnrMF.

10. McCallum AD, Sloan DJ. The importance of clinical pharmacokinetic–pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes. Int J Pharmacokinet **2017**; 2:195–212. Available at: http://europepmc.org/articles/PMC6161803.

11. Prideaux B, Via LE, Zimmerman MD, et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med **2015**; 21:1223–1227. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26343800.

12. Dheda K, Lenders L, Magombedze G, et al. Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis. Am J Respir Crit Care Med **2018**; 198:1208–1219.

13. Rodvold KA, Yoo L, George JM. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents. Clin Pharmacokinet **2011**; 50:689–704. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21973267.

14. Rodvold KA, George JM, Yoo L. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet **2011**; 50:637–664. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21895037.

15. Lodise TP, Drusano GL, Butterfield JM, Scoville J, Gotfried M, Rodvold KA. Penetration of vancomycin into epithelial lining fluid in healthy volunteers. Antimicrob Agents Chemother **2011**; 55:5507–5511. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21911567.

16. Boselli E, Breilh D, Rimmele T, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med **2005**; 33:1529–1533.

17. Conte JE, Golden JA, Kipps JE, Lin ET, Zurlinden E. Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. Clin Pharmacokinet **2004**; 43:395–404. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15086276.

18. Conte Jr. JE, Golden JA, McQuitty M, et al. Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. Antimicrob Agents Chemother **2002**; 46:2358–2364. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12121905.

19. Conte Jr. JE, Golden JA, Duncan S, McKenna E, Zurlinden E. Intrapulmonary concentrations of pyrazinamide. Antimicrob Agents Chemother **1999**; 43:1329–1333. Available at: https://www.ncbi.nlm.nih.gov/pubmed/10348747.

20. Conte Jr. JE, Golden JA, Kipps J, Lin ET, Zurlinden E. Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations. Antimicrob Agents Chemother **2001**; 45:2891–2896. Available at: https://www.ncbi.nlm.nih.gov/pubmed/11557486.

21. Ziglam HM, Baldwin DR, Daniels I, Andrew JM, Finch RG. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother **2002**; 50:1011–1015. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12461025.

22. Goutelle S, Bourguignon L, Jelliffe RW, Conte Jr. JE, Maire P. Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin. J Theor Biol **2011**; 282:80–92. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21605569.

23. Collins AM, Rylance J, Wootton DG, et al. Bronchoalveolar lavage (BAL) for research; obtaining adequate sample yield. J Vis Exp **2014**; Available at: https://www.ncbi.nlm.nih.gov/pubmed/24686157.

24. Ralph AP, Ardian M, Wiguna A, et al. A simple, valid, numerical score for grading chest X-ray severity in adult smear-positive pulmonary tuberculosis. Thorax **2010**; 65:863–869. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20861290.

25. Ministry of Health Malawi. National Tuberculosis Control Programme Manual 7th Edition. **2012**;

26. Ministry of Health Malawi. Clinical Management of HIV in Children and Adults. 2014.

27. Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother **2008**; 52:24–36. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17846133.

28. Grigg J, Kleinert S, Woods RL, et al. Alveolar epithelial lining fluid cellularity, protein and endothelin-1 in children with congenital heart disease. Eur Respir J **1996**; 9:1381–1388.

29. Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs **2014**; 74:839–854. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24846578.

30. Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis **2009**; 48:1685–1694. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19432554.

31. World Health Organization. Guidelines for treatment of tuberculosis. Geneva: WHO, 2010.

32. Stott KE, Pertinez H, Sturkenboom MGG, et al. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. J Antimicrob Chemother **2018**; Available at: https://watermark.silverchair.com/dky152.pdf?token=AQECAHi208BE49Ooan9kkhW\_Ercy7Dm3ZL\_9Cf3qfKAc485ysgAAAbIwggGuBgkqhkiG9w0BBwagggGfMIIBmwIBADCCAZQGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMRUVNAVG7N992XQjYAgEQgIIBZdFDS6Ko7OVZYRUqzsArVssOBWNcXbcmOi7gP2P-D\_X3kFdh.

33. van Oosterhout JJ, Dzinjalamala FK, Dimba A, et al. Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi. Antimicrob Agents Chemother **2015**; 59:6175–6180. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26248378.

34. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother **2006**; 50:1170–1177. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1426981/pdf/0719-05.pdf.

35. Denti P, Jeremiah K, Chigutsa E, et al. Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania. PLoS One **2015**; 10:e0141002. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26501782.

36. Gumbo T, Dona CS, Meek C, Leff R. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother **2009**; 53:3197–3204. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19451303.

37. Gumbo T, Louie A, Liu W, et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother **2007**; 51:2329–2336. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17438043.

38. Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother **2007**; 51:3781–3788. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17724157.

39. Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis **2010**; 201:1225–1231. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20210628.

40. Boeree MJ, Diacon AH, Dawson R, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med **2015**; 191:1058–1065. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25654354.

41. Svensson RJ, Svensson EM, Aarnoutse RE, et al. Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations. J Infect Dis **2018**; Available at: https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy242/4989841?redirectedFrom=fulltext.

42. Jeremiah K, Denti P, Chigutsa E, et al. Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV. Antimicrob Agents Chemother **2014**; 58:3468–3474. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068463/pdf/zac3468.pdf.

43. Sloan DJ, Mwandumba HC, Garton NJ, et al. Pharmacodynamic modelling of bacillary elimination rates and detection of bacterial lipid bodies in sputum to predict and understand outcomes in treatment of pulmonary tuberculosis. Clin Infect Dis **2015**; Available at: http://cid.oxfordjournals.org/content/early/2015/03/31/cid.civ195.full.pdf.

44. Schon T, Jureen P, Giske CG, et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother **2009**; 64:786–793. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19633001.

**Table 1**: Demographic and clinical description of cohort

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic** | **Total** **(n=157)** | **Intrapulmonary arm (n=51)** | **Plasma arm** **(n=106)** |
| Age (years), median [IQR] | 34 [28-39] | 32 [26-36] | 34 [28-41] |
| Male sex, n (%) | 120 (76.4) | 44 (86.3) | 76 (71.7) |
| Weight (kg), median [IQR] | 51.1 [46.9-55.6] | 50.0 [47.3-53.8] | 52.0 [46.6-56.5] |
| Body mass index (kg/m2), median [IQR] | 18.4 [17.0-19.8] | 17.9 [16.8-18.9] | 18.7 [17.1-20.1] |
| HIV-infected, n (%) | 91 (58.0) | 23 (45.1) | 68 (64.2) |
| Baseline CD4 count in HIV-infected patients (cells/mm3), median [IQR] (n=91) | 178 [80-285] | 178 [93-273] | 175 [77-284] |
| On antiretroviral therapy at baseline if HIV-infected, n (%) | 39 (42.9) | 10 (43.5) | 29 (42.6) |
| Rifampicin/isoniazid/pyrazinamide/ethambutol dose (mg), n (%)300/150/800/550450/225/1200/825600/300/1600/1100750/375/2000/1375 | 3 (1.9)107 (68.2)45 (28.7)2 (1.3) | 1 (2.0)38 (74.5)12 (23.5)0 (0.0) | 2 (1.9)69 (65.1)33 (31.1)2 (1.9) |
| Adherence, n (%) a Missed no doses Missed 1-2 doses Missed >2 doses | 135 (86.0)14 (8.9)8 (5.1) | 41 (80.4)6 (11.8)4 (7.8) | 94 (88.7)8 (7.5)4 (3.8) |

IQR: interquartile range

a Adherence assessed by direct questioning and pill counts

**Table 2**: Final steady state parameter estimates for drug exposure (AUC and Cmax) in plasma, epithelial lining fluid, and alveolar cells

|  |  |  |  |
| --- | --- | --- | --- |
| **Drug** | **Pharmaco-kinetic index** | **Plasma therapeutic drug monitoring target** [29] | **Matrix** |
| **Plasma****(median [IQR])** | **Epithelial lining fluid****(median [IQR])** | **Alveolar cells (median [IQR])** |
| Rifampicin | AUC (μg.h/ml)AUC (μg.h/ml)Cmax (μg/ml)Cmax (μg/ml) | ---≥ 8 μg/ml | 6.6 [5.6-7.5] a30.6 [27.3-36.7] b0.8 [0.3-1.0] a 4.0 [3.5-4.8] b | 65.7 [52.4-77.1]7.8 [6.4-10.0] | 46.0 [36.4-55.1]5.3 [4.4-7.6] |
| Isoniazid | AUC (μg.h/ml)Cmax (μg/ml) | -≥ 3 μg/ml | 19.0 [11.9-25.9]2.6 [2.4-3.0] | 277.8 [154.9-382.4]38.9 [32.8-46.2] | 24.4 [14.1-34.8]3.5 [2.9-4.2] |
| Pyrazinamide | AUC (μg.h/ml)Cmax (μg/ml) | -≥ 20 μg/ml c | 319.5 [292.0-384.3]24.0 [22.2-26.3] | 16,062 [14,096-19,403]1,195 [1,062-1,361] | 1,036 [899-1,272]78 [68-94] |
| Ethambutol | AUC (μg.h/ml)Cmax (μg/ml) | -≥ 2 μg/ml | 5.4 [2.9-7.4]1.3 [1.1-1.6] | 22.6 [11.7-29.2]5.2 [4.2-6.6] | 83.0 [48.0-110.1]20.0 [15.4-25.3] |

AUC: area under the concentration-time curve; Cmax: peak concentration; IQR: interquartile range

a Estimated unbound fraction of rifampicin in plasma, assuming typical 80% rifampicin protein binding

b Total rifampicin in plasma

c Pyrazinamide Cmax ≥ 35 μg/ml has also been proposed as a target due to association with improved outcomes [30]

**Table 3**: Summary of pharmacokinetic indices from modelled plasma data

|  |  |  |
| --- | --- | --- |
| **Drug** | **Simulated plasma median AUC/MIC [IQR]** | **Simulated plasma median Cmax/MIC [IQR]** |
| Rifampicin a | 2,319 [1422-3786] | 285.0 [178.3-456.2] |
| Isoniazid | 448 [438-458] | 75.4 [66.7-85.3] |
| Pyrazinamide b | - | - |
| Ethambutol | 64 [17-239] | 4.0 [1.1-14.6] |

Minimum inhibitory concentration (MIC) data available from baseline isolates from 88 participants. Using the mean and standard deviation for AUC, Cmax, and MIC from this dataset, 100,000 AUC/MIC and Cmax/MIC pairings generated using Monte Carlo simulation to estimate the data distribution.

a Rifampicin AUC and Cmax based on total (protein bound + unbound) drug

b MIC data not available for pyrazinamide

**Table 4**: Pharmacokinetic indices and treatment response

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Pharmacokinetic parameter** | **Odds ratio for 2-month culture conversion** **(95% CI)** | ***P* value** | **Odds ratio for favourable outcome (95% CI)** | ***P* value** |
| **Drug** | **Matrix** | **Pharmacokinetic index** |
| Rifampicin | Plasma | AUC (μg.h/ml) | 1.01 (0.95-1.07) | 0.815 | 1.03 (0.95-1.14) | 0.488 |
| C­max­ (μg/ml) | 1.02 (0.73-1.44) | 0.918 | 1.68 (0.91-3.47) | 0.125 |
| Epithelial lining fluid a | AUC (μg.h/ml) | 1.02 (1.00-1.04) | 0.118 | 1.09 (0.99-1.43) | 0.321 |
| C­max­ (μg/ml) | 1.17 (1.01-1.45) | 0.085 | 2.03 (0.97-9.24) | 0.221 |
| Alveolar cells a | AUC (μg.h/ml) | 1.00 (0.99-1.02) | 0.607 | 1.00 (0.99-1.05) | 0.836 |
| C­max­ (μg/ml) | 1.05 (0.93-1.19) | 0.429 | 1.03 (0.89-1.43) | 0.801 |
| Isoniazid | Plasma | AUC (μg.h/ml) | 0.98 (0.94-1.02) | 0.281 | 1.07 (0.99-1.18) | 0.100 |
| C­max­ (μg/ml) | 1.24 (0.58-2.68) | 0.583 | 3.79 (0.96-17.86) | 0.071 |
| Epithelial lining fluid a | AUC (μg.h/ml) | 1.00 (1.00-1.00) | 0.372 | 1.00 (1.00-1.01) | 0.575 |
| C­max­ (μg/ml) | 1.02 (1.00-1.04) | 0.116 | 1.03 (0.98-1.15) | 0.400 |
| Alveolar cells a | AUC (μg.h/ml) | 1.00 (0.98-1.02) | 0.992 | 1.00 (0.98-1.06) | 0.980 |
| C­max­ (μg/ml) | 1.04 (0.85-1.30) | 0.674 | 1.01 (0.73-1.77) | 0.959 |
| Pyrazinamide | Plasma | AUC (μg.h/ml) | 1.00 (0.99-1.00) | 0.303 | 1.00 (1.00-1.01) | 0.751 |
| C­max­ (μg/ml) | 1.01 (0.91-1.13) | 0.869 | 1.07 (0.90-1.29) | 0.464 |
| Epithelial lining fluid a | AUC (μg.h/ml) | 1.00 (1.00-1.00) | 0.652 | 1.00 (1.00-1.00) | 0.356 |
| C­max­ (μg/ml) | 1.00 (1.00-1.00) | 0.217 | 1.00 (1.00-1.01) | 0.341 |
| Alveolar cells a | AUC (μg.h/ml) | 1.00 (1.00-1.00) | 0.276 | 1.00 (1.00-1.00) | 0.443 |
| C­max­ (μg/ml) | 1.00 (0.99-1.01) | 0.483 | 1.01 (0.99-1.06) | 0.489 |
| Ethambutol | Plasma | AUC (μg.h/ml) | 1.08 (0.92-1.27) | 0.360 | 0.91 (0.71-1.17) | 0.465 |
| C­max­ (μg/ml) | 0.85 (0.32-2.29) | 0.743 | 1.12 (0.25-5.86) | 0.889 |
| Epithelial lining fluid a | AUC (μg.h/ml) | 0.97 (0.82-1.12) | 0.658 | 1.06 (0.89-1.73) | 0.733 |
| C­max­ (μg/ml) | 0.98 (0.70-1.35) | 0.878 | 1.05 (0.71-2.32) | 0.856 |
| Alveolar cells a | AUC (μg.h/ml) | 0.99 (0.95-1.02) | 0.469 | 1.07 (0.97-1.28) | 0.345 |
| C­max­ (μg/ml) | 0.98 (0.91-1.05) | 0.584 | 1.11 (0.92-1.55) | 0.420 |

AUC: area under the concentration-time curve; Cmax: peak concentration

a Analysis restricted to those in the intrapulmonary group

**Figure Legends**

**Figure 1**: **Concentration-time plots for rifampicin, isoniazid, pyrazinamide and ethambutol in plasma, epithelial lining fluid, and alveolar cells**

Summary concentration-time plots for rifampicin, isoniazid, pyrazinamide, and ethambutol in plasma, epithelial lining fluid, and alveolar cells from population means at steady state. To account for rifampicin protein-binding, the red/pink shaded area in the top-left panel illustrates plasma drug exposure for total drug (top line) or unbound drug (bottom line), assuming 80% protein-binding in plasma and negligible protein-binding in epithelial lining fluid. Plasma concentrations for isoniazid, pyrazinamide, and ethambutol shown as total drug only. Concentrations at the different timepoints were calculated using the Bayesian posterior pharmacokinetic parameter value estimates, and epithelial lining fluid:plasma (*RELF*) and alveolar cells:plasma (*RAC*) ratios. The horizontal dotted line represents the plasma targets for therapeutic drug monitoring [29].

**Figure 2: Baseline drug sensitivity**

Drug sensitivity in baseline sputum *Mycobacterium tuberculosis* isolates determined using microtitre plates (n=88). Pyrazinamide was not assessed due to its’ need for acidic test conditions. The minimum inhibitory concentration (MIC) was recorded as the lowest concentration in the microtitre plate with no visible growth observed. The currently recommended critical concentration (breakpoint) is indicated by the dashed line [44].